Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.47 |
| ▸ | CES1 | P23141 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | F2R | P25116 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzamide SCHEMBL18921209 | 0.84 | PARP1 (0.47) | PKMALDH1A1ALOX15F2RDGAT1 | |
| SCHEMBL4649267 | 0.83 | CES2 (0.47) | CES2CES1PKMALDH1A1ALOX15 | |
| SCHEMBL31315010 | 0.83 | CES2 (0.47) | CES2CES1PKMALDH1A1ALOX15 | |
| SCHEMBL25270267 | 0.83 | CES2 (0.50) | CES2CES1PKMALDH1A1ALOX15 | |
| SCHEMBL111637 | 0.81 | KEAP1 (0.53) | CES2CES1PKMALDH1A1F2R | |
| SCHEMBL9834572 | 0.80 | CES2 (0.52) | CES2CES1ALDH1A1ALOX15KEAP1 | |
| SCHEMBL23198421 | 0.80 | FLT1 (0.42) | F2R | |
| SCHEMBL20560213 | 0.79 | PKM (0.40) | CES2CES1PKMALDH1A1ALOX15 | |
| SCHEMBL120277 | 0.79 | F2R (0.48) | CES2CES1PKMALDH1A1F2R | |
| SCHEMBL30480694 | 0.79 | F2R (0.48) | CES2CES1PKMALDH1A1F2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109503416-A | A kind of miscellaneous Shandong amine intermediate synthetic method of grace | 常州智超化学有限公司 | 2019-03-22 | — | — | CN | claimed |
| US-20250382304-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-12275742-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-12077528-B2 | Preparation method for deuterated macrocyclic compound | SHENZHEN TARGETRX, INC. (CN) | 2024-09-03 | — | — | US | disclosed |
| CN-118271331-A | Gelsemin derivatives, synthesis method and application thereof in inhibiting tumor cell proliferation | 赣江中药创新中心 | 2024-07-02 | — | — | CN | disclosed |
| US-11667649-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| CN-115916196-A | Heteroaromatic macrocyclic ether chemotherapeutic agents | 纽威伦特公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-4146205-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | Nuvalent, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| US-20230076627-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT, INC. | 2023-03-09 | — | — | US | disclosed |
| US-20220340586-A9 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT, INC. | 2022-10-27 | — | — | US | disclosed |
| US-6090803-A | ANTIDIABETIC AGENTS; INCONTINENCE | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-07-18 | — | — | US | disclosed |
| EP-1000059-A1 | TRICYCLIC VASOPRESSIN AGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-05-17 | — | — | EP | disclosed |
| EP-1000062-A1 | TRICYCLIC VASOPRESSIN AGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999006409-A1 | TRICYCLIC VASOPRESSIN AGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-02-11 | — | — | WO | disclosed |
| WO-1999006403-A1 | TRICYCLIC VASOPRESSIN AGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-02-11 | — | — | WO | disclosed |
| CN-1031378-C | Combating insect infestation in rice | ROHM & HAAS (US) | 1996-03-27 | — | — | CN | disclosed |
| CN-1046835-A | Go out and remove the method for rice insect pest | ROHM & HAAS (US) | 1990-11-14 | — | — | CN | disclosed |
| EP-0124476-B1 | CARBOXAMIDES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | CIBA-GEIGY AG (CH) | 1988-06-22 | — | — | EP | disclosed |
| US-4559349-A | TREATMENT OF PHYCHOSIS | CIBA GEIGY CORPORATION (US) | 1985-12-17 | — | — | US | disclosed |
| EP-0124476-A1 | Carboxamides, process for their preparation and pharmaceutical preparations containing them | CIBA-GEIGY AG (CH) | 1984-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12275742-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | CYP2C8, ABCB1, PAICS | CES2 205/4885CES1 769/4885PKM 2617/4885 |
| US-11667649-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | CYP2C8, ABCB1, PAICS | CES2 205/4885CES1 769/4885PKM 2617/4885 |
| US-20230076627-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | CYP2C8, ABCB1, PAICS | CES2 205/4885CES1 769/4885PKM 2617/4885 |
| US-20250382304-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | CYP2C8, ABCB1, PAICS | CES2 205/4885CES1 769/4885PKM 2617/4885 |
| US-12077528-B2 | Preparation method for deuterated macrocyclic compound | CTRC, GCG, SBDS | CES2 1885/4885CES1 2606/4885PKM 1459/4885 |
| US-20220340586-A9 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | ABCB1, CYP2C8, PAICS | CES2 212/4885CES1 804/4885PKM 2543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.